CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 114 enrolled
Drug / intervention
Buprenorphine transdermal patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01961271
NCT01961271Phase 4Completed
CompareCT.gov

Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia

Mundipharma Pte Ltd.·interventional·Posted Oct 11, 2013·Updated Sep 23, 2016

In Brief

A Phase 4 clinical trial evaluating Buprenorphine transdermal patch for Osteoarthritis and 4 related conditions. Completed, enrolled 114 participants across 16 sites in 3 countries.

Detailed Summary

The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, who are not adequately responding to non-opioid painkillers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain, Muscle Pain
CountriesHong Kong, Philippines, South Korea
CollaboratorsMundipharma Korea Ltd, Mundipharma (Hong Kong) Ltd, Mundipharma Distribution GmBH (Philippine Branch)

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 11, 2013
Enrollment StartJun 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 12.7 years ago

Interventions

Buprenorphine transdermal patchdrug

Please see Arm Description.